A TAK-007 Pivotal Study in Patients with Relapsed or Refractory B-Cell Malignancies
Latest Information Update: 14 Jan 2021
At a glance
- Drugs TAK 007 (Primary)
- Indications Haematological malignancies
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 11 Jan 2021 According to a Takeda media release, this pivotal study is expected to begin enrolling patients with relapsed or refractory B-cell malignancies in 2021.
- 05 Aug 2020 New trial record
- 31 Jul 2020 According to Takeda media release, cohort expansion ongoing for a pivotal study planned for next year and potential approval in FY2023.